BR112022013585A2 - Esteroides neuroativos e composição farmacêutica que contém os mesmos - Google Patents
Esteroides neuroativos e composição farmacêutica que contém os mesmosInfo
- Publication number
- BR112022013585A2 BR112022013585A2 BR112022013585A BR112022013585A BR112022013585A2 BR 112022013585 A2 BR112022013585 A2 BR 112022013585A2 BR 112022013585 A BR112022013585 A BR 112022013585A BR 112022013585 A BR112022013585 A BR 112022013585A BR 112022013585 A2 BR112022013585 A2 BR 112022013585A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- same
- composition containing
- neuroactive steroids
- neuroactive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959977P | 2020-01-12 | 2020-01-12 | |
| PCT/US2021/013112 WO2021142477A1 (en) | 2020-01-12 | 2021-01-12 | Neuroactive steroids and pharmaceutical composition containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013585A2 true BR112022013585A2 (pt) | 2022-09-13 |
Family
ID=76788885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013585A BR112022013585A2 (pt) | 2020-01-12 | 2021-01-12 | Esteroides neuroativos e composição farmacêutica que contém os mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230118577A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087854A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023509798A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230031812A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115244065B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021206712A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013585A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167331A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294606A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008614A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142477A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020231837A1 (en) | 2019-05-10 | 2020-11-19 | Brii Biosciences, Inc. | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof |
| JP7670626B2 (ja) * | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| AU2021238346A1 (en) | 2020-03-18 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN115974950A (zh) * | 2022-12-23 | 2023-04-18 | 上海彩迩文生化科技有限公司 | 一种3-烷基化的甾体中间体及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1359646A (fr) * | 1962-11-22 | 1964-04-30 | Roussel Uclaf | Procédé de préparation de dérivés stéroïdes et produits obtenus par ce procédé |
| NL6808141A (cg-RX-API-DMAC7.html) * | 1967-06-16 | 1968-12-17 | ||
| GB1409239A (en) * | 1971-11-11 | 1975-10-08 | Glaxo Lab Ltd | Process for the preparation of 3alpha-hydroxy-5alpha-steroids |
| PH12018501923B1 (en) * | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| WO2018013613A1 (en) * | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| JP7670626B2 (ja) * | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| WO2021174205A1 (en) * | 2020-02-27 | 2021-09-02 | Brii Biosciences, Inc. | Prodrugs of neuroactive steroids |
-
2021
- 2021-01-12 WO PCT/US2021/013112 patent/WO2021142477A1/en not_active Ceased
- 2021-01-12 CN CN202180020110.2A patent/CN115244065B/zh active Active
- 2021-01-12 CA CA3167331A patent/CA3167331A1/en active Pending
- 2021-01-12 US US17/792,319 patent/US20230118577A1/en not_active Abandoned
- 2021-01-12 IL IL294606A patent/IL294606A/en unknown
- 2021-01-12 KR KR1020227027899A patent/KR20230031812A/ko active Pending
- 2021-01-12 EP EP21738878.4A patent/EP4087854A4/en active Pending
- 2021-01-12 MX MX2022008614A patent/MX2022008614A/es unknown
- 2021-01-12 JP JP2022542380A patent/JP2023509798A/ja active Pending
- 2021-01-12 AU AU2021206712A patent/AU2021206712A1/en not_active Abandoned
- 2021-01-12 BR BR112022013585A patent/BR112022013585A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021142477A1 (en) | 2021-07-15 |
| JP2023509798A (ja) | 2023-03-09 |
| EP4087854A1 (en) | 2022-11-16 |
| EP4087854A4 (en) | 2024-02-28 |
| CA3167331A1 (en) | 2021-07-15 |
| US20230118577A1 (en) | 2023-04-20 |
| CN115244065A (zh) | 2022-10-25 |
| MX2022008614A (es) | 2022-10-10 |
| KR20230031812A (ko) | 2023-03-07 |
| IL294606A (en) | 2022-09-01 |
| CN115244065B (zh) | 2025-09-09 |
| AU2021206712A1 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008614A (es) | Esteroides neuroactivos y composicion farmaceutica que contiene los mismos. | |
| Wu et al. | How urban versus rural residency relates to COVID-19 vaccine hesitancy: A large-scale national Chinese study | |
| BR112022021831A2 (pt) | Dispositivos de liberação transdérmica de fármacos tendo micro projeções revestidas com psilocibina, dietilamida do ácido lisérgico ou 3,4-metilenodioximetanfetamina | |
| BR112023001957A2 (pt) | Composições e métodos para inibir expressão de lpa | |
| BR112018076114A2 (pt) | composições tópicas de apremilast | |
| BR112018067998A2 (pt) | esteróides neuroativos, composições e usos destes | |
| BR112022021823A2 (pt) | Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
| BR112023022524A2 (pt) | Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos | |
| CL2024002767A1 (es) | Moduladores de nlrp3 | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| BR112022024840A2 (pt) | Combinação de alcaftadina e um corticosteroide | |
| BR112021024534A2 (pt) | Métodos para o tratamento da deficiência de alfa-1 antitripsina (aatd) | |
| BR112019023820A2 (pt) | moduladores duplos de receptor de farnesoide x e epóxido hidrolas solúvel | |
| BR112022020392A2 (pt) | Método para tratar um indivíduo que tem doença de huntington, inibidor do bromodomínio 9, e, uso de um inibidor do bromodomínio 9 | |
| BR112022021535A2 (pt) | Métodos para tratar agitação associada ao mal de alzheimer | |
| BR112022020882A2 (pt) | Tratamento da hidradenite supurativa | |
| BR112023026559A2 (pt) | Formas cristalinas de trofinetida | |
| BR112022008639A2 (pt) | Tratamento de distúrbios do fígado | |
| Andani et al. | The effect of lavender aromatherapy to improve the sleep quality of the elderly at Tresna Werdha Abiyoso Social Service Center, Sleman | |
| Ahmad et al. | Outcome of manipulation under anaesthesia in adhesive capsulitis patients | |
| BR112022010677A2 (pt) | Uso de reboxetina para tratar transtornos do sistema nervoso | |
| BR112022013160A2 (pt) | Dextrometadona como tratamento modificador de doença para transtornos e doenças neuropsiquiátricos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07J 13/00 , C07J 31/00 , C07J 41/00 Ipc: C07J 13/00 (2006.01), C07J 31/00 (2006.01), C07J 4 |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |